Some people with rectal cancer may be able to avoid chemotherapy, radiation and major surgery after a new US approval for the immunotherapy drug dostarlimab. The decision applies only to a specific ...

A newly approved immunotherapy was effective for some forms of rectal cancer without the need for additional treatments.

The approval only covers a narrow group of rectal cancer patients, but for them it may rewrite what treatment looks like.

Some people with rectal cancer may now be able to skip chemotherapy, radiation and surgery. The U.S. Food and Drug ...

The FDA on Monday granted accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) to help select patients with ...

The FDA just approved Jemperli for some adults with locally advanced rectal cancer, offering an effective immunotherapy ...

Some people with rectal cancer may now be able to skip chemotherapy, radiation and surgery. The U.S. Food and Drug ...

A 5-year analysis supports watch-and-wait as an option for patients with locally advanced disease who have a complete response to neoadjuvant therapy.

Ryan Moore, MD, discusses the choice between surgery and total neoadjuvant therapy (TNT) for rectal cancer and when watch-and ...

Patients treated for rectal cancer at hospitals that are accredited by the American College of Surgeons (ACS) National Accreditation Program for Rectal Cancer (NAPRC) were less likely to have cancer ...

The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining ...

For more than 12 years, Abbott's cancer diagnostics business has helped expand access to colorectal cancer screening through ...